Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease

The MDS Scientific Issues Committee

doi:10.1002/mds.28837

Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease

The MDS Scientific Issues Committee

Neurology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	264-267
Number of pages	4
Journal	Movement Disorders
Volume	37
Issue number	2
DOIs	https://doi.org/10.1002/mds.28837
State	Published - Feb 2022

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.28837

Cite this

@article{39d04d0cd83a40a58b373c4751891905,

title = "Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease",

author = "{The MDS Scientific Issues Committee} and Lewis, {Simon J.G.} and Factor, {Stewart A.} and Nir Giladi and Mark Hallett and Alice Nieuwboer and Nutt, {John G.} and Serge Przedborski and Papa, {Stella M.}",

note = "Funding Information: S.J.G.L. was supported by a National Health and Medical Research Council Leadership Fellowship (1195830) and has received research funding from The Michael J. Fox Foundation and the Australian Research Council. S.A.F. was supported by The Sartain Lanier Family Foundation. He been a consultant for Lundbeck, Sunovion, Biogen, Impel, Acorda, and CereSpir. He has received education and research grants from Medtronics, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Biohaven, Impax, Lilly, US World Meds, Sunovion Therapeutics, Neurocrine, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation, The Michael J. Fox Foundation, National Institutes of Health (NIH), and Parkinson's Foundation. He receives royalties from Demos, Blackwell Futura, Springer for textbooks, and UpToDate. Other support was from Signant (Bracket Global LLC) and CNS Ratings LLC. N.G. serves as consultant to Sionara, NeuroDerm, Pharma2B, Denali, Neuron23, Sanofi‐Genzyme, Biogen, and AbbVie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at AbbVie, Sanofi‐Genzyme, and Movement Disorder Society. He received research support from The Michael J. Fox Foundation, the National Parkinson Foundation, European Union, and Israel Science Foundation, as well as from Teva NNE program, Biogen, and Ionis. He receives support from the Sieratzki Family Foundation and the Aufzien Academic Center in Tel‐Aviv University. M.H. is an inventor of patents held by the NIH for an immunotoxin for the treatment of focal movement disorders and the H‐coil for magnetic stimulation; in relation to the latter, he has received license‐fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health and Brainsway (both unpaid positions). He is on the editorial board of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, Wiley, Wolters Kluwer, and Elsevier. He has research grants from Medtronic, Inc. for a study of deep brain stimulation for dystonia and CALA Health for studies of a device to suppress tremor. A.N. received funding from the European Commission, Research Foundation Flanders, King Baudouin Foundation, The Michael J. Fox Foundation, Jacques and Gloria Gossweiler Foundation, and KU Leuven Internal Research Funds. S.M.P. has received research support from the NIH, National Institute of Neurological Disorders and Stroke; The Michael J. Fox Foundation; Pfizer, Inc.; EnVivo Pharmaceuticals, Inc.; Forum Pharmaceuticals, Inc.; GeneGraft, LTD; Key Neurosciences; and Mochida Pharmaceuticals Co. LTD. She has been a consultant for Teva Neuroscience. The authors have no conflict of interest with this manuscript. Funding Information: S.J.G.L. was supported by a National Health and Medical Research Council Leadership Fellowship (1195830) and has received research funding from The Michael J. Fox Foundation and the Australian Research Council. S.A.F. was supported by The Sartain Lanier Family Foundation. He been a consultant for Lundbeck, Sunovion, Biogen, Impel, Acorda, and CereSpir. He has received education and research grants from Medtronics, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Biohaven, Impax, Lilly, US World Meds, Sunovion Therapeutics, Neurocrine, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation, The Michael J. Fox Foundation, National Institutes of Health (NIH), and Parkinson's Foundation. He receives royalties from Demos, Blackwell Futura, Springer for textbooks, and UpToDate. Other support was from Signant (Bracket Global LLC) and CNS Ratings LLC. N.G. serves as consultant to Sionara, NeuroDerm, Pharma2B, Denali, Neuron23, Sanofi‐Genzyme, Biogen, and AbbVie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at AbbVie, Sanofi‐Genzyme, and Movement Disorder Society. He received research support from The Michael J. Fox Foundation, the National Parkinson Foundation, European Union, and Israel Science Foundation, as well as from Teva NNE program, Biogen, and Ionis. He receives support from the Sieratzki Family Foundation and the Aufzien Academic Center in Tel‐Aviv University. M.H. is an inventor of patents held by the NIH for an immunotoxin for the treatment of focal movement disorders and the H‐coil for magnetic stimulation; in relation to the latter, he has received license‐fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health and Brainsway (both unpaid positions). He is on the editorial board of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, Wiley, Wolters Kluwer, and Elsevier. He has research grants from Medtronic, Inc. for a study of deep brain stimulation for dystonia and CALA Health for studies of a device to suppress tremor. A.N. received funding from the European Commission, Research Foundation Flanders, King Baudouin Foundation, The Michael J. Fox Foundation, Jacques and Gloria Gossweiler Foundation, and KU Leuven Internal Research Funds. S.M.P. has received research support from the NIH, National Institute of Neurological Disorders and Stroke; The Michael J. Fox Foundation; Pfizer, Inc.; EnVivo Pharmaceuticals, Inc.; Forum Pharmaceuticals, Inc.; GeneGraft, LTD; Key Neurosciences; and Mochida Pharmaceuticals Co. LTD. She has been a consultant for Teva Neuroscience. The authors have no conflict of interest with this manuscript. Relevant conflicts of interest/financial disclosures: ",

year = "2022",

month = feb,

doi = "10.1002/mds.28837",

language = "English (US)",

volume = "37",

pages = "264--267",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease

AU - The MDS Scientific Issues Committee

AU - Lewis, Simon J.G.

AU - Factor, Stewart A.

AU - Giladi, Nir

AU - Hallett, Mark

AU - Nieuwboer, Alice

AU - Nutt, John G.

AU - Przedborski, Serge

AU - Papa, Stella M.

N1 - Funding Information: S.J.G.L. was supported by a National Health and Medical Research Council Leadership Fellowship (1195830) and has received research funding from The Michael J. Fox Foundation and the Australian Research Council. S.A.F. was supported by The Sartain Lanier Family Foundation. He been a consultant for Lundbeck, Sunovion, Biogen, Impel, Acorda, and CereSpir. He has received education and research grants from Medtronics, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Biohaven, Impax, Lilly, US World Meds, Sunovion Therapeutics, Neurocrine, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation, The Michael J. Fox Foundation, National Institutes of Health (NIH), and Parkinson's Foundation. He receives royalties from Demos, Blackwell Futura, Springer for textbooks, and UpToDate. Other support was from Signant (Bracket Global LLC) and CNS Ratings LLC. N.G. serves as consultant to Sionara, NeuroDerm, Pharma2B, Denali, Neuron23, Sanofi‐Genzyme, Biogen, and AbbVie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at AbbVie, Sanofi‐Genzyme, and Movement Disorder Society. He received research support from The Michael J. Fox Foundation, the National Parkinson Foundation, European Union, and Israel Science Foundation, as well as from Teva NNE program, Biogen, and Ionis. He receives support from the Sieratzki Family Foundation and the Aufzien Academic Center in Tel‐Aviv University. M.H. is an inventor of patents held by the NIH for an immunotoxin for the treatment of focal movement disorders and the H‐coil for magnetic stimulation; in relation to the latter, he has received license‐fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health and Brainsway (both unpaid positions). He is on the editorial board of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, Wiley, Wolters Kluwer, and Elsevier. He has research grants from Medtronic, Inc. for a study of deep brain stimulation for dystonia and CALA Health for studies of a device to suppress tremor. A.N. received funding from the European Commission, Research Foundation Flanders, King Baudouin Foundation, The Michael J. Fox Foundation, Jacques and Gloria Gossweiler Foundation, and KU Leuven Internal Research Funds. S.M.P. has received research support from the NIH, National Institute of Neurological Disorders and Stroke; The Michael J. Fox Foundation; Pfizer, Inc.; EnVivo Pharmaceuticals, Inc.; Forum Pharmaceuticals, Inc.; GeneGraft, LTD; Key Neurosciences; and Mochida Pharmaceuticals Co. LTD. She has been a consultant for Teva Neuroscience. The authors have no conflict of interest with this manuscript. Funding Information: S.J.G.L. was supported by a National Health and Medical Research Council Leadership Fellowship (1195830) and has received research funding from The Michael J. Fox Foundation and the Australian Research Council. S.A.F. was supported by The Sartain Lanier Family Foundation. He been a consultant for Lundbeck, Sunovion, Biogen, Impel, Acorda, and CereSpir. He has received education and research grants from Medtronics, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Biohaven, Impax, Lilly, US World Meds, Sunovion Therapeutics, Neurocrine, Vaccinex, Voyager, Jazz Pharmaceuticals, CHDI Foundation, The Michael J. Fox Foundation, National Institutes of Health (NIH), and Parkinson's Foundation. He receives royalties from Demos, Blackwell Futura, Springer for textbooks, and UpToDate. Other support was from Signant (Bracket Global LLC) and CNS Ratings LLC. N.G. serves as consultant to Sionara, NeuroDerm, Pharma2B, Denali, Neuron23, Sanofi‐Genzyme, Biogen, and AbbVie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at AbbVie, Sanofi‐Genzyme, and Movement Disorder Society. He received research support from The Michael J. Fox Foundation, the National Parkinson Foundation, European Union, and Israel Science Foundation, as well as from Teva NNE program, Biogen, and Ionis. He receives support from the Sieratzki Family Foundation and the Aufzien Academic Center in Tel‐Aviv University. M.H. is an inventor of patents held by the NIH for an immunotoxin for the treatment of focal movement disorders and the H‐coil for magnetic stimulation; in relation to the latter, he has received license‐fee payments from the NIH (from Brainsway). He is on the Medical Advisory Boards of CALA Health and Brainsway (both unpaid positions). He is on the editorial board of approximately 15 journals and receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer, Wiley, Wolters Kluwer, and Elsevier. He has research grants from Medtronic, Inc. for a study of deep brain stimulation for dystonia and CALA Health for studies of a device to suppress tremor. A.N. received funding from the European Commission, Research Foundation Flanders, King Baudouin Foundation, The Michael J. Fox Foundation, Jacques and Gloria Gossweiler Foundation, and KU Leuven Internal Research Funds. S.M.P. has received research support from the NIH, National Institute of Neurological Disorders and Stroke; The Michael J. Fox Foundation; Pfizer, Inc.; EnVivo Pharmaceuticals, Inc.; Forum Pharmaceuticals, Inc.; GeneGraft, LTD; Key Neurosciences; and Mochida Pharmaceuticals Co. LTD. She has been a consultant for Teva Neuroscience. The authors have no conflict of interest with this manuscript. Relevant conflicts of interest/financial disclosures:

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85121691467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121691467&partnerID=8YFLogxK

U2 - 10.1002/mds.28837

DO - 10.1002/mds.28837

M3 - Article

C2 - 34939228

AN - SCOPUS:85121691467

SN - 0885-3185

VL - 37

SP - 264

EP - 267

JO - Movement Disorders

JF - Movement Disorders

IS - 2

ER -

Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this